Provided by Tiger Trade Technology Pte. Ltd.

SINO BIOPHARM

5.890
+0.0400.68%
Volume:110.67M
Turnover:645.95M
Market Cap:110.50B
PE:39.95
High:5.970
Open:5.850
Low:5.680
Close:5.850
52wk High:9.120
52wk Low:3.137
Shares:18.76B
HK Float Shares:18.76B
Volume Ratio:1.48
T/O Rate:0.59%
Dividend:0.10
Dividend Rate:1.73%
EPS(LYR):0.147
ROE:12.53%
ROA:5.56%
PB:3.17
PE(LYR):39.95
PS:3.06

Loading ...

Sino Biopharmaceutical FY2025 profit attributable to owners of the parent from continuing operations rises 22% to RMB2.34 billion; revenue grows 10.3% to RMB31.83 billion

Reuters
·
Mar 26

Sino Biopharmaceutical FY Net Income Attributable RMB 2,343.35 Million

THOMSON REUTERS
·
Mar 26

Sino Biopharmaceutical Stock Advances 3.1% in Hong Kong, Outperforms Competitors

Dow Jones
·
Mar 24

SINO BIOPHARM Achieves MSCI ESG Rating Upgrade to AA Level

Stock News
·
Mar 23

Sino Biopharmaceutical upgraded to AA in MSCI ESG Ratings

Reuters
·
Mar 23

Sino Biopharmaceutical Stock Slips 4.3% in Hong Kong

Dow Jones
·
Mar 23

Sino Biopharmaceutical Stock Slides 3.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Mar 19

Earning Preview: SINO BIOPHARM revenue is expected to increase by 6%, and institutional views are bullish

Earnings Agent
·
Mar 19

Sino Biopharmaceutical Gets China Nod for Osteoarthritis Drug Trial

MT Newswires Live
·
Mar 17

China Biopharma's Novel Drug TRD221 Receives NMPA Clearance for Clinical Trials

Stock News
·
Mar 17

BRIEF-Sino Biopharmaceutical Says TRD221 Receives NMPA Clinical Trial Approval For Osteoarthritis Treatment

Reuters
·
Mar 17

Sino Biopharmaceutical - Trd221 Receives Nmpa Clinical Trial Approval for Osteoarthritis Treatment

THOMSON REUTERS
·
Mar 17

Sino Biopharm (01177) Sets 26 Mar 2026 Board Meeting to Approve FY 2025 Results and Mull Final Dividend

Bulletin Express
·
Mar 16

Sino Biopharmaceutical Stock Advances 2.4% in Hong Kong

Dow Jones
·
Mar 16

Sino Biopharmaceutical wins NMPA CDE consent to submit TQB3454 bile duct cancer marketing application

Reuters
·
Mar 16

Sino Biopharmaceutical Stock Slides 1.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Mar 13

Sino Biopharmaceutical Unit's Biliary Tract Cancer Drug Trial Reaches Primary Endpoints of Survival

MT Newswires Live
·
Mar 12

BRIEF-Sino Biopharmaceutical Reports Positive Results On Phase III Clinical Study Of TQB3454 IDH1 Inhibitor

Reuters
·
Mar 12

SINO BIOPHARM (01177) achieves first-in-China Phase III success for IDH1 inhibitor TQB3454; NMPA filing imminent

Bulletin Express
·
Mar 12

Thailand's Wealthiest Family Prepares Another IPO

Deep News
·
Mar 12